Figure 5.

MRI results from a male patient diagnosed four months earlier with glioblastoma, IDH-wildtype, and treated with surgery followed by standard-of-care radiotherapy and concomittant temozolomide. Progression was questioned at the time of this MRI exam (three days prior to re-do surgery). (A, B) Post-contrast T₁-weighted and (C, D) rCBV maps shown for two representative images slices. (E, F) FTB were created and show a mixture of tumor (red) and treatment effect (white), which is consistent with the pathologic diagnosis of tumor and treatment effect, respectively. Note that without the previously determined rCBV thresholds to distinguish tumor from treatment effect, the “blush” of higher rCBV noted on the rCBV maps would be difficult to interpret.